Utah Medical Products, Inc. (UTMD) Is At $76.80 Formed Wedge; Bank Hapoalim Bm Increased Orbotech LTD (ORBK) Position

November 15, 2017 - By Clifton Ray

Utah Medical Products, Inc. (UTMD) formed wedge up with $82.94 target or 8.00% above today’s $76.80 share price. Utah Medical Products, Inc. (UTMD) has $285.62 million valuation. The stock increased 1.92% or $1.45 during the last trading session, reaching $76.8. About shares traded. Utah Medical Products, Inc. (NASDAQ:UTMD) has declined 0.94% since November 15, 2016 and is downtrending. It has underperformed by 17.64% the S&P500.

Bank Hapoalim Bm increased Orbotech Ltd (ORBK) stake by 38.09% reported in 2017Q2 SEC filing. Bank Hapoalim Bm acquired 18,213 shares as Orbotech Ltd (ORBK)’s stock rose 18.15%. The Bank Hapoalim Bm holds 66,032 shares with $2.15 million value, up from 47,819 last quarter. Orbotech Ltd now has $2.51 billion valuation. The stock decreased 1.41% or $0.75 during the last trading session, reaching $52.49. About shares traded. Orbotech Ltd (NASDAQ:ORBK) has risen 49.39% since November 15, 2016 and is uptrending. It has outperformed by 32.69% the S&P500.

Bank Hapoalim Bm decreased Starbucks Corp (NASDAQ:SBUX) stake by 8,800 shares to 28,978 valued at $1.69M in 2017Q2. It also reduced Select Sector Spdr Tr (XLK) stake by 5,925 shares and now owns 167,934 shares. Jpmorgan Chase & Co (NYSE:JPM) was reduced too.

Among 10 analysts covering Orbotech (NASDAQ:ORBK), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Orbotech had 20 analyst reports since September 8, 2015 according to SRatingsIntel. The stock has “Buy” rating by Jefferies on Thursday, October 19. The rating was maintained by RBC Capital Markets with “Outperform” on Friday, November 6. The rating was maintained by Oppenheimer with “Outperform” on Wednesday, December 2. Needham maintained it with “Buy” rating and $26 target in Monday, November 16 report. On Thursday, December 10 the stock rating was maintained by Needham with “Buy”. Oppenheimer maintained the stock with “Buy” rating in Thursday, August 3 report. The company was maintained on Thursday, November 2 by Barclays Capital. The rating was maintained by Oppenheimer on Thursday, August 10 with “Buy”. On Tuesday, November 7 the stock rating was maintained by Needham with “Buy”. As per Wednesday, November 1, the company rating was maintained by Oppenheimer.

Investors sentiment decreased to 1.38 in Q2 2017. Its down 0.05, from 1.43 in 2017Q1. It turned negative, as 6 investors sold Utah Medical Products, Inc. shares while 20 reduced holdings. 10 funds opened positions while 26 raised stakes. 2.40 million shares or 4.65% more from 2.30 million shares in 2017Q1 were reported. Janney Montgomery Scott Ltd Liability Com has 0% invested in Utah Medical Products, Inc. (NASDAQ:UTMD). Ontario – Canada-based Manufacturers Life Company The has invested 0% in Utah Medical Products, Inc. (NASDAQ:UTMD). Nationwide Fund Advisors stated it has 7,771 shares. The Illinois-based Ativo Capital Mngmt Ltd Liability Com has invested 0.33% in Utah Medical Products, Inc. (NASDAQ:UTMD). Legal & General Public Limited Company accumulated 836 shares. Denali Advisors Ltd Liability Corporation holds 0% or 33 shares in its portfolio. Penobscot Inv Management owns 4,000 shares. Schwab Charles has invested 0% of its portfolio in Utah Medical Products, Inc. (NASDAQ:UTMD). Ameritas Inv Prns accumulated 296 shares or 0% of the stock. Seizert Capital Ptnrs Limited Liability Corp holds 0.02% or 6,512 shares in its portfolio. 53,294 are owned by Northern Tru Corporation. Tfs Limited Company invested in 3,226 shares or 0.09% of the stock. Strs Ohio reported 2,700 shares. Moreover, California Employees Retirement System has 0% invested in Utah Medical Products, Inc. (NASDAQ:UTMD) for 16,950 shares. American Group Incorporated invested in 0% or 2,118 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

>